Joint whole exome sequencing and linkage analysis in a multigenerational family segregating Type 1 Diabetes by Mereu, Elisabetta
!
 
          "#$%&'($)*!+&,-$!.)/+$!+$!01,-$1'$!
!
!
!"##"$%#"&!'&$'()$(%&'*&
Terapia Pediatrica e Farmacologia dello Sviluppo 
0$2-3!44566!
!
+,-./&01,23&34,53&63783.9-.:&;.<&2-.=;:3&;.;2>6-6&-.&;&
582/-:3.3?;/-,.;2&@;5-2>&63:?3:;/-.:&#>A3&B&!-;C3/36&
!
.&))3'&!(2$&#)$7$23!+$(2$8-$#1'&!+$!177&'&#91!
:;<=>?!@!A&#&)$21!:&+$21!
!
 
 
B'&(&#)1)1!+1C! ;-$(1D&))1!:&'&/!
!
033'+$#1)3'&!<3))3'1)3C! !B'37E!B13-3!:3$!
!
F/)3'(=G&-1)3'$C! <3))E((1!.&'&#1!.1##1H!B'37E!B13-3!:3$!
&
 
 
 
;(1I&!7$#1-&!1##3!1221+&I$23!J>K?!@!J>KL!
 
Elisabetta Mereu gratefully acknowledges Sardinia Regional Government
for the financial support of her PhD scholarship ( P.O.R. Sardegna F.S.E.
Operational Programme of the Autonomous Region of Sardinia,
European Social Fund 2007-2013 - Axis IV Human Resources, Objective
l.3, Line of Activity l.3.1.).
ii
Acknowledgements
This work was supported by resources from the National Research Coun-
cil (CNR) of Cagliari - Istituto di Ricerca Genetica e Biomedica (IRGB).
The project was conceived by the Director of the Institute Prof. Francesco
Cucca, who also provided reagents and funding sources. I am thank-
ful to the colleagues who contributed to this project, in particular the
Immunogenetics, Genotyping and Sequencing Platforms (GSP) and High-
Performance Computing (HPC) laboratories at CRS4 in Pula, as well as the
genotyping and statistical groups at the IRGB Institute. I also thank the
group of biologists at IRGB who is carrying out functional experiments on
the preliminary results of this thesis.
I acknowledge the special contribution of all the volunteers participating
in this research project and all the clinicians and physicians for their con-
tinuous eﬀort in patients’enrollment. I am especially grateful to my tutors
Serena Sanna and Prof. Paolo Moi for their continuous advices, and to
the Director of the IRGB Institute Prof. Francesco Cucca for involving me
iv Acknowledgements
in this project. Finally, I also thank my family, friends and colleagues for
supporting me morally in this diﬃcult but exciting research experience.
Contents
Acknowledgements iii
1 Introduction 1
1.1 Rare variants in complex diseases . . . . . . . . . . . . . . . . 5
1.2 Next generation sequencing to detect rare variants in com-
plex diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2.1 Whole exome sequencing . . . . . . . . . . . . . . . . 7
1.2.2 Low-Pass DNA Sequencing of 2120 Sardinians . . . . 10
2 Genetics of Type 1 Diabetes 13
2.1 Many faces of diabetes . . . . . . . . . . . . . . . . . . . . . . 13
2.2 From linkage studies to whole-exome sequencing in Type 1
Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3 Type 1 Diabetes in Sardinia . . . . . . . . . . . . . . . . . . . 16
3 Study design and Methods 19
vi Contents
3.1 Subjects and study design . . . . . . . . . . . . . . . . . . . . 19
3.2 Whole exome sequencing . . . . . . . . . . . . . . . . . . . . 21
3.2.1 Quality Controls of reads . . . . . . . . . . . . . . . . 24
3.2.2 Variant calling and analysis of variants . . . . . . . . 27
3.2.3 Strategy of analysis . . . . . . . . . . . . . . . . . . . . 32
3.3 Linkage Analysis . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.3.1 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
4 Concluding Remarks 43
Bibliography 47
Chapter 1
Introduction
In the past decade, genetic analyses of complex diseases were carried out
using a systematic evaluation of the genome, known as genome-wide as-
sociation scan (GWAS). This approach consists in an examination of many
(hundreds of thousands) common genetic variants in thousands of indi-
viduals to see if any variant is associated with a trait. The underlying
idea is that common diseases must be driven by common variants, theory
also known as common variant - common disease hypothesis [1]. To date,
GWAS had highlighted thousands of common genetic loci associated with
diseases susceptibility and findings are reproducible across populations.
Despite its success, this approach has also limitations. In the most cases,
GWAS hits fall outside of annotated genes, limiting our understanding on
their molecular function. Furthermore, these associations have often very
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small eﬀects on diseases’risk and account only for a modest portion of
the estimated genetic components of many diseases, leaving a substantial
fraction unknown [2]. Several hypothesis have been made on where the
missing heritability is [2]. One attributes a major role to rare variants, a
category of genetic changes that are present in < 1% of the population,
mostly ignored by GWAS.
Today, the advent of next-generation sequencing (NGS) has revolutionized
the study of genetic variations, as the entire spectrum of genomic variation
can be assessed, including rare variants. Cost to sequence all exons or
genomes has considerably reduced, allowing sequencing of increasingly
large number of samples.
Whole-genomesequencing represents themost completevariant-discovery
strategy, and a common strategy in large scale studies is to incorporate
whole-genome sequencing information into GWAS with inferential meth-
ods known as genotype imputation [3]. Exome sequencing only focuses
on coding regions and thus limits the spectrum of variants tested, but has
been widely applied as a powerful alternative cost-eﬀective approach to
detect rare coding variants, which often havemoremarked functional con-
sequences [4] [5]. Specifically, exome-sequencing technologies have been
mostly important for the identification ofmolecular defects in patientswith
Mendelian disorder or as a diagnostic tool in case of suspected rare genetic
disorder [6]. This success led researchers to extend it in the case of complex
diseases, in order to identify rare coding variants that are not detected by
3GWAS [7]. Rare variants however are hard to identify in the large scale
population studies used in GWAS: their often occur too infrequently to
allow association testing in a suﬃcient number of individuals. One strat-
egy is to focus on cohorts that were initially collected for linkage analysis -
i.e., families with multiple aﬀected individuals ; in the assumption that af-
fected individuals drawn from the same familymust share the same causal
variant, families are a natural enriched setting for very rare variants, as the
same variant will be carried by multiple chromosomes. The challenge in
such analyses is that even randomly selected individuals in any family
will share substantial fractions of their genomes in common, therefore the
prioritization of individual variants detected trough sequencing involves
additional criteria. For example, a combination of exome sequencing in
key individuals with family-based linkage analysis using classical geno-
typing arrays in the full family may increases power to detect rare genetic
variants with large eﬀect size. In fact, exome sequencing allows detection
of a set of potential candidate rare variants, and linkage analysis will help
to distinguish those that are disease-causing by evaluating co-segregation
with the phenotype within the family. Examples of successful applica-
tions of whole-exome sequencing in family-based designs [8][9], also with
a limited number of cases [10], have been already reported for complex
diseases [8].
In this PhD thesis, Iwill present an application of a joint exome sequenc-
ing and linkage analysis in a multigenerational family withmultiple mem-
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bers aﬀected by Type 1 Diabetes (T1D), a form of diabetes mellitus that re-
sults from the autoimmune destruction of the insulin-producing beta cells
in the pancreas and that is usually diagnosed in children and young adults.
From this family, we recruited 13 members in 3 generations, 9 of which
were aﬀected. All samples were genotyped for about 700, 000 common
variants using the Illumina OmniExpress array, and exome-sequencing
was carried in 3 aﬀected individuals (one per generation) and a healthy
individual (pedigree is showed in Figure 1.1).
Figure 1.1: The patients family tree showing selected individuals in the exome-seq
and linkage analysis.
The thesis is organized as follows:
• Chapter 2 describes the state of the art in current literature on genetics
of Type 1 diabetes.
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• Chapter 3 details methods and analysis protocols, including descrip-
tion of the samples, study design and workflow in whole-exome
sequencing analysis, from the reads alignment, variant calling, in-
cluding reads quality controls to the variant annotations, filtering
and association analysis. I will also present data processing and
quality for the genotyping arrays, which will be integrated with
exome-sequencing in a parametric linkage analysis on the family.
• Chapter 4 will be dedicate to conclusions and future developments
of this project.
1.1 Rare variants in complex diseases
Ourunderstandingon thegenetic architectureof complexdiseases changed
quite rapidly with the advent of the GWAS approach. In particular, for
most of the diseases it appears that heritability follows a polygenic model,
with tens or even hundreds variants modulating the diseases risk. GWAS
have extensively searched for common variants with large or moderate
eﬀects, and resulting observations show that the total contribution of this
category of variants to the disease does not fully explain the estimated
genetic heritability [12]. In fact, as statistical power in GWAS depends
by a combination of eﬀect size and minor allele frequency, many disease
susceptibility loci with either a very small eﬀect size or highly-penetrant
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rare alleles have been missed by the GWAS approach.
Several population genetic studies suggest that low and rare variants tend
to be recent in origin and support their possible contribute to disease risk,
being enriched for potentially functional mutations [15] [16]. Such vari-
ants are likely to be seen in families with a number of aﬀected individuals
exciding expectations based on the overall population risk. Family-based
studies are thus valuable in the search of rare variants.
1.2 Next generation sequencing to detect rare variants
in complex diseases
Over the past fewyears, scientific discoveriesmade throughwhole genome
and exome sequencing grew exponentially, accelerating genetic studies
on Mendelian and complex diseases and increasing the total number of
known genomic variations. Large international eﬀorts, as the Exome Se-
quencing Project1 (ESP) and 1000 Genomes Project2 (1000G), have sequenced
thousands of individuals from diﬀerent nationality, with the common goal
to characterize the geographic and functional spectrum of human ge-
netic variation [14]. The 1000 Genomes project includes sequencing of
2535 individuals sampled from 26 populations drawn from the five con-
tinents, analyzed through diﬀerent levels of resolution. The overall num-
1https://esp.gs.washington.edu/drupal/
2http://www.1000genomes.org/
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ber of variations discovered is 79 million sites, including biallelic single-
nucleotide polymorphisms (SNPs), insertion, deletions (indels), complex
short substitutions and other structural variant classes [14]. The NHLBI
Exome Sequencing Project sequenced the coding region of 15, 585 genes
by whole-exome sequencing in up to 6500 individuals of African and Eu-
ropean ancestry, finding thousands of very rare variants, some of which
are population-specific [16]. Therefore, sequencing of human genomes
and exomes revealed that most low and rare variants showed substantial
geographic diﬀerentiation and that the majority of protein-coding varia-
tion predicted functionally important were rare [14] [16]. Characterization
of such variants, likely evolutionarily recent and under a weak selection
pressure [16], will allow a better interpretation of their functional role in
specific studies.
1.2.1 Whole exome sequencing
Whole exome sequencing (WES) is a technique to selectively capture and
sequence protein-coding regions in parallel through high-throughput se-
quencing. Similarly to whole-genome sequencing, the targeted DNA is
sequenced by dividing it in millions of small fragments that are then
sequenced in parallel concurrently. Then all fragments are assembled
back together by aligning the sequenced nucleotides to a known reference
genome or by algorithms for de-novo assembly.
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Experimental workflow consists on preparing genomic DNA libraries and
hybridizing them to capture arrays and then sequencing short targeted
fragments. Each fragment usually is in the range of 300 − 500 bps and
specific adapters are added to their ends in order to allow their attach-
ment and sequencing. Single DNAmolecules separated in a solid support,
called Flow Cell, are clonally amplified and in parallel sequenced.
Results of sequencing are generated by reading optical signals during iter-
ative cycles of polymerase-mediated nucleotide extensions or, in one ap-
proach, through successive oligonucleotide ligations [18]. Data produced
by a single run are more than 600 gigabases of nucleotide sequence, called
reads, with a length ranging in 25 − 100 bps. A such parallel sequencing
process allows an overlapping of many randomDNA fragments, therefore
each nucleotide, in target region, will be read in many diﬀerent reads, de-
termining his depth coverage. Depending on the design selected, we can
have sequencing runs targeted to single end or paired end reads. In paired
end runs a fragment is first sequenced from one end to the other end for up
to 25 − 100 bases (depending on what decided by the the researcher), then
another round of reading is performed in the opposite way. The paired
end designs improves mapping quality during the process of alignment as
the corresponding DNA fragment in the reference genome can identified
more confidently.
There are diﬀerent commercially available exome sequencing platforms
that capture a slightly diﬀerent set of target regions, being some also fo-
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cused on regulatory regions as promoters and exon-intron junction region.
For example, the three sequencing platforms from Agilent, Illumina and
Nimblegen target 51 Mb, 62 Mb and 64 Mb respectively, with 29.45 Mb in
common among all and 4.428 Mb of unique target regions. However, eﬃ-
ciency and overall coverage of strict coding regions has been shown to be
highly concordant [17].
Whatever is the platformutilized, data process and rawdata checks have to
follow standard rules to assure quality of data. Specifically, once sequenc-
ing reads have been generated, they are aligned to the reference genome
and assigned a probability for the matching in a specific genomic position.
Base quality scores have to be recalibrated to correct for variation in qual-
ity with machine cycle and sequence context. Reads that are identical to
others (duplicated reads) are marked and removed, as they are likely to
be potential PCR artifacts [21]. At this point is important a careful quality
assessment of sequencing run performance, through summary statistics of
key parameters. More details are given in section 3.2.1. Aftermapping and
quality process, reads are then analyzed to call genotypes at polymorphic
sites, a process known as variant calling. Details are given in section 3.2.2.
Variants are then filtered with a strategy that will depend on the hypothe-
sized inheritancemodel, diseasespenetrance andexpected frequencyof the
causative variance, and prioritized according to their biological predicted
function. This process of filtering has been very successfull for monogenic
diseases, where only one, highly penetrant, deleterious variant is expected
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to be the causal mutation. For complex diseases, where multiple variants
can contribute to the clinical outcome, we are often unable to discriminate
real disease-causing genetic variants from the broader background of rare
variants present in all human genomes, which are not pathogenic for the
disease under investigation. In such cases, more extensive genetic analyses
or biological characterization of variants are necessary to pinpoint to the
causative site.
1.2.2 Low-Pass DNA Sequencing of 2120 Sardinians
The huge data resources available from international large scale projects,
such as 1000 Genomes projet, allowed the discovery of a large number of
low and rare novel variants in individuals from a broad set of popula-
tions, including admixed samples [14]. Furthermore, it has emerged that
low-frequency variants show substantial geographic diﬀerentiation [14]
and that founder isolated populations are likely to underrepresented in
this large eﬀort. For example, it was shown that, 1000G Consortium iden-
tified 50%, 98% and 99.7% of the SNPs with frequencies of 0.1%, 1.0%
and 5.0% identified after sequencing 2500 samples from UK. By contrast,
only 23.7%, 76.9% and 99.3% of SNPs in the same frequency range iden-
tified after sequencing 2000 Sardinian samples were also detected in the
1000 Genomes project. Therefore, despite this large international eﬀorts,
population-specific whole-genome sequencing studies are thus valuable,
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in particular for the characterization of rare population-specific variants.
Many research groups are undertaking whole-genome sequencing in their
population of interest. In Sardinia, one large eﬀort, carried out by the
IRGB-CNR Institute and led by prof. Francesco Cucca in collaboration
with prof. Goncalo Abecasis of the University of Michigan, is the Sardinia
Medical Sequencing Project. It involves whole-genome sequencing of 2120
Sardinian samples at an average coverage of 4x, whom 1122 are volunteers
of the SardiNIA project [25] and others were enrolled in aMultiple Sclerosis
(MS) and Type 1 Diabetes (T1D) case-control study [24]. The sequencing
eﬀort led to the discovery of 17, 617122 single-nucleotide polymorphisms
(SNPs), of which 21.6% were not identified in any other population (based
on dbSNP 142 and the Exome Aggregation Consortium)3. For the work I
present in this PhD thesis, I was able to use this resource to flag and discard
variants shared among aﬀected family members but that were unlikely to
be associated with the diseases, being rare in elsewhere in Europe but
common in Sardinia, or absent elsewhere by present in other non-aﬀected
Sardinians.
3http://exac.broadinstitute.org/
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Chapter 2
Genetics of Type 1 Diabetes
2.1 Many faces of diabetes
Type 1 diabetes (T1D) is a common, complex and autoimmune disease
where genetic, epigenetic and environmental factors contribute to risk. It
manifests itself through an autoimmune destruction of pancreatic β cells,
resulting in a lack of production of insulin [28]. Data from large epidemi-
ologic studies showed that over the last few decades, there has been an
increase in the worldwide incidence of T1D by 2 − 5% [29], suggesting
the importance of environmental factors in the etiology of disease [34].
On the other hand, genetic predisposition is evident from the significant
familial clustering. In fact, the average prevalence risk in children of an
aﬀected parent ranges from 2 to 8%, in dizygotic twin is about 8%, and in
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monozygotic twins is as high as 50% ( 30% within 10 years of diagnosis of
the first twin), numbers that are considerably higher than the 0.4% risk of
the general population [30][31][33].
Type 1 Diabetes represents the most common type of diabetes in children
and young adults and historically was known as Juvenile Diabetes; the typ-
ical adult form of diabetes is instead known as Type 2 Diabetes (T2D).
Diabetes tends to be divided into these two major categories, but other
minor and monogenic forms exist, highlighting the wide disease’s het-
erogeneity. For example, a common subgroup of T1D and T2D is LADA
(latent autoimmune diabetes), which appears to be an admixture of the two
forms of diabetes, sharing common symptoms and underlying genetic risk
factors [36][39]. LADA is usually diagnosed over 30 − 35 years of age and
for at least the firsts six months is unlikely to need insulin treatment [38].
The diagnosis is mostly based on GAD antibody positivity, a parameter
also used for T1D diagnosis [36], therefore misspecification is not infre-
quent [38][36].
There also exist monogenic forms of diabetes, as MODY (Maturity-Onset-
Diabetes of the Young), a subtype of familial diabetes characterized by early
onset (usually before 25 years old in Caucasians) and specific autosomal
dominant mutations in thirteen genes [36][40]. However, heterogeneity is
present also in this class.
It is likely that many familial forms are clinically misclassified as type 1 or
type 2 diabetes, as often the excess of aﬀect members contrasts with the
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expectations based on population incidence estimates. In depth studies
of such families can help to understand the genetics of these peculiar dis-
ease manifestations, and will provide new insights into the pathogenesis
of more common forms of diabetes.
2.2 From linkage studies to whole-exome sequencing
in Type 1 Diabetes
Multiple linkage studies showed that the HLA locus, on chromosome
6p21.3, represent themajor risk factor for T1D, explaining up to 40−50% of
the familial clustering [32]. 1 Non-HLA loci, contributing to T1D, in partic-
ular INS gene, CTLA4,PTPN22 and IL2RA, have been associated through
studies based on gene candidate approach.
Since 2007, several GWAS and meta-analysis have confirmed the role of
such genes and up to date 57 independent T1D susceptibility loci outside
the major HLA are established. Many of these loci contain genes relevant
for the immune response and also expressed in pancreatic beta-cell, rein-
forcing the idea that immune system and beta-cell function are important
for T1D pathogenesis [36][37][41][42]. Overall, the identified genetic fac-
tors explains a large fraction of the heritability (about 80% , of an overall
estimate of 88% [43] )[36].
1This strong association with HLA did not consistently replicate in T2D, confirming
that T1D and T2D are two distinct diseases.
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Although this is an exception compared to other complex human diseases,
many familial T1D cases cannot be explained by their HLA status or higher
genetic burden of risk-alleles at the 57 non-HLA loci. Therefore, genetic
studies are now concentrating on families and applying novel technolo-
gies, as next-generation sequencing, to achieve a deep characterization of
the genetic background. A successful eﬀort has been reported in Biason-
Lauber et al., where authors studied a family with multiple individuals,
of which four were aﬀected by T1D, one by ulcerative colitis and some-
one had an unclear diabetes phenotype. By using a combined approach
of diﬀerent technologies −− microsatellite genotyping, targeted deep se-
quencing, exome-sequencing and Sanger sequencing of relevant candidate
genes −− , they identified a mutation in the SIRT1 gene carried only by the
members aﬀected by an autoimmune disorder [45], therefore suggesting a
new mutation for a monogenic form of T1D [45].
2.3 Type 1 Diabetes in Sardinia
Epidemiological studies consistently show that Sardinia and Finland rep-
resent the two most high-risk areas for T1D worldwide [46]. Furthermore,
a 5-fold increased prevalence of T1D has been observed in Sardinian MS
patients, in the same individuals and/or in the same families. From the
study ofMarrosu et al. has emerged that associations of both T1D and MS
with common variants in the HLA region explain only a small part of the
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co-occurrence of these two autoimmunes diseases [44], suggesting the in-
volvement of one or more damaging Sardinian-specific variants aﬀecting
the immune system.
Investigations in families with more individuals aﬀected by T1D in multi-
ple generations, and/or also in presence of double autoimmune disorders,
could represent a strength point in genetic studies of T1D, particularly
in a genetically isolated population as Sardinia, where T1D (and MS) are
common and there is evidence of powerful founder eﬀects [47].
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Chapter 3
Study design and Methods
3.1 Subjects and study design
The family used in this studywas initially enrolled on 1993 by the team led
by Prof. Francesco Cucca. Fresh specimens of already enrolled volunteers
and extension to the newly aﬀected individuals was carried out from 2010.
All members are of Sardinian origin and there is not consanguinity. A
written informed consent was obtained from all participants (14 individ-
uals). Among all volunteers, 10 were diagnosed Type 1 Diabetes trough
autoantibodies (GAD, IA2 and IAA) tests and two also suﬀered of a second
autoimmune disease (Celiac disease or Multiple Sclerosis). Age at disease
onset is highly variable, from 6 to 62 years (average 18.12 years). The other
volunteers were healthy individuals, although some of them were posi-
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tive for autoantibodies tests. A graphical representation of the pedigree is
showed in Figure 3.1.
The pattern of inheritance among the aﬀected family members was indica-
tive of an autosomal dominant mutation. A linkage analysis was previ-
ously performed with microsatellite genotyping. Here, we used whole
exome sequencing and linkage analysis with the integration of SNPs de-
rived from commercial whole-genome genotyping arrays and from exome
sequencing. Further, a previous linkage analysis with microsatellite geno-
typing has been performed.
We sequenced the exome of four members from this family: three aﬀected
individuals across three diﬀerent generations and one healthy, as showed
in Figure 3.1. Exome sequencing was performed in a single experimental
run with other 38 individuals (sixteen T1D aﬀected parent-oﬀspring pairs
and 6 individuals aﬀected by Multiple Sclerosis or Type 1 Diabetes from
other Sardinian multigenerational families).
Furthremore, thirteen members of the family were extensively genotyped
through Ilumina OmniExpress beadchips, a genotyping array targeting
about 750K SNPs. The hypothesis of this study is to identify rare (MAF
< 1%) genetic variants with large eﬀect size, therefore a joint linkage anal-
ysis with exome sequencing in this family seems optimal because the same
mutation can be observed in many relatives and cosegregation with T1D
can be tested.
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Figure 3.1: The pedigree of the family enrolled. Aﬀection status of each member
and individuals selected for sequenced are highlighted as described in the legend.
3.2 Whole exome sequencing
Whole exome of 42 individuals was captured by the Illumina TruSeq Ex-
ome Enrichment Kit, followed by sequencing using Illumina HiSeq 2000
sequencer. This Illumina kit provides an high uniform coverage across 62
Mb of exomic sequence, including 5￿ UTR, 3￿ UTR, microRNA, and other
non-codingRNA, for a total of 20, 794 genes. The experimentwas designed
to sequenced paired-end reads of 100-bp length, and each sample was run
in diﬀerent lanes to reach the targeted coverage (60x). The 42 samples were
sequenced in 5 runs, with twelve subjects been replicated in two of these
to improve their initial coverage, as showed in figure 3.2.
The reads were aligned to the hs37d5 reference assembly from the 1000
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Figure 3.2: Diﬀerences in mean depth for 12 samples in first and in final run (a).
Histograms of mean depth. (b).
Human Genome Project through Burrows-Wheeler Aligner (BWA [48])
version 0.6.2 and alignments for each sample were converted to a binary
format for storing sequence data (BAM format), sorted by reference coor-
dinate and indexed. A BAM file format ( as well as in a SAM format -
similar to bam, but in readable text format ) is subdivided in two sections:
header and alignment. The header section contains general information
about the file, such as BAM file format version and sorting order of the
alignments, which can be sorted by the reference coordinates, by query
names, or unsorted. Other information include the sample identification
code, the read group, the lane or the program used for alignement. The
alignment section provides information for each sequence about mapping
and quality with respect to the reference genome. By a Cigar String for
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each sequence read, it is possible to know the number of bases that match
or mismatch with the reference, how many are deleted or inserted.
At this point information for the same sample derived from diﬀerent lanes
was merged in an unique BAM file which was then processed with the
dedup option in bamUtil1 to determine duplicates. Then annotated with
MarkDuplicates - an utility from the package Picard-tools 1.812 for marking
PCR duplicates. In fact, duplicates may cause biases and alter variant call-
ing results, because sequencing errors will be propagated in duplicates.
After marking duplicates, the caller will be able to consider only one read
among the duplicates and will more likely work in the right way.
After this step, reads were re-aligned if they map near known polymor-
phisms or insertions and deletions (according to the GATK3 pipeline (ver-
sion 2.7.4), then base qualities were recalibrated after all these processes.
Finally, overlapping read pairs were cropped with the ClipOverlap option
on the bamUtil executable. Each BAM file is then assessed for quality
before being taken forward for the variant calling step, that we carried out
with the toolGATKHaplotypeCaller to call indels and SNPs simultaneously.
A schematic view of the described process is represented in Figure 3.3.
1http://genome.sph.umich.edu/wiki/BamUtil
2 http://picard.sourceforge.net/
3https://www.broadinstitute.org/gatk/
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Figure 3.3: Workflow applied to NGS data processing
3.2.1 Quality Controls of reads
Data quality assessment represents a crucial step in next generation se-
quencing studies and it is much more complex in respect to traditional
array platforms. Therefore, in order to diagnose sequencing run prob-
lems, a series of quality assessments was performed for all samples and
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in all sequencing runs. Data quality is assessed through empirical and re-
ported base quality score by comparing aligned bases to the reference
genome. Empirical base scores are calculated in Phred Score Q, with
Q = −10 · log10(Perr), where Perr = Prob(Error of called base). For example,
Phred Score of 20 indicates that chances that this base is called incorrectly
are 1% and a Pred Score of 30 correspond to an error probability of 0.1%,
or, in other words, a base call accuracy of 99.9%.
In figure 3.4, empirical against reported Phred scores from two diﬀerents
kits (SureSelect Target Enrichment System Kit and the newest TruSeq Ex-
ome Enrichment Kit) for five samples is shown. In the left panel, a clear
deviation from the diagonal and overall lower quality is evident, indi-
cating that the run was problematic. These samples (except one) have
been sequenced a second time through the kit chosen for this study, and
the empirical versus reported Phred score, represented in the right panel,
shows that the experiment was now carried out properly. Other quality
controls are showed in figures 3.6 and 3.7. For example, distribution of
insert size shows that mean values range between 230 and 270 bp, which
is close to the expected mean insert size for this Illumina kit (where mean
expected insert size is 230 bp). Another factor that is important to con-
sider in NGS experiments is the GC content, as it interferes with library
amplification [49]. Therefore regions with extreme GC content may be
under-represented, in accord with the figure 3.6, where low and high GC
regions have low coverage, suggesting a higher error rate for these regions.
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Figure 3.4: Empirical Phred score in a run showingdeviation fromReportedPhred
(a) and in a run with a better trend (b)
Statistics as mean depth, empirical Q20 counts, number of mapped
reads, percentage of duplicates as well as others are then compared among
all samples in order to identify batches eﬀects and other heterogeneities
between samples. In figure 3.8 the number of total, mapped, paired,
duplicated and failed reads for each sample in a specific run are plotted.
These flag statistics have been useful not only to see diﬀerences across
samples in the same run, but also in diﬀerent sequencing runs.
After mapping and quality filters, a total of 112 million of reads have been
mapped on target regions, with a mean depth of 57.19x and 98% with at
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Figure 3.5: Number of samples for each run. Run1 and run2 have twelve subjects
in common.
least a Q-score of 20.
3.2.2 Variant calling and analysis of variants
After quality checks, realignments and recalibration procedure, we started
the process of variant calling. We used HaplotypeCaller of Genome Analysis
Toolkit (GATK), which calls SNPs and short indels simultaneously across all
BAM files. Haplotype Caller employs a local de novo assembly algorithm
that represents an agnostic approach with regards to variant type and di-
vergence fromany reference[22]. Furthermore, by jointly analyzing several
samples, it extracts information from the other sequenced chromosomes,
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Figure 3.6: Insert size distribution in a run (a). Mean depth vs GC in a sample (b).
Figure 3.7: Mean depth and empirical Q20 count (a). Base count in milion vs
reported Phred Score in a recalibrated run data (b).
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Figure 3.8: Flag statistics in one of the analyzed runs (a). Average values of
principal flagstats in all runs (b).
resulting in higher variants discovery rates. In addition to Haplotype
Caller, in accord to Best Practices from GATK forum, a quantification of
the goodness of called variants was performed through Variant Quality
score Recalibrator, that assigns accurate confidence scores to each mutation
and by statistical models is able to filter out false positive calls.
Variants are stored by the program in a VCF (Variant Calling Format) file.
This is a text filewith a specific format that iswidely recognized. It contains
meta-information lines, a header line, and then data lines each containing
information about a position in the genome. The header section includes
information about format file, genome reference file and a key for each
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annotation data. The section of variants has nine principal field:
• chromosome;
• physical position;
• rsID;
• reference allele and alternative allele(s);
• a quality score that depends on the caller;
• a binary filter (PASS or not PASS) if a variant quality score has been
applied;
• an INFO field with some information that can be for example the
number of alternative alleles in genotypes and alternative allele fre-
quency, total number of alleles in called genotypes, total depth in this
region and other annotations useful to define a variant quality score;
• a FORMAT field to define following information about genotypes in
sample fields.
Subsequent columns are those corresponding to each individual genotype,
written as 0/0, 0/1 or 1/1, where 0 represents the reference allele and 1 the
alternative allele. Generally, after the genotypes there are allelic depth and
a genotype likelihood, separated by a colon. A quick analysis of the VCF
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file with vcftool4 allows to have a general idea about the overall number
of variants, divided by SNPs and indels, number of shared and private
variants across all samples and number of transitions and transversions
changes and their ratio. Graphics below show barplots for each of these
numbers in all samples, highlighting similarity in their frequencies, except
in the sample 26, which is the only individual sequenced with a diﬀerent
kit.
Figure 3.9: Barplots of overall number of SNPs and indels for sample (a).
Transitions-transversions ratio for sample (b).
4http://sourceforge.net/projects/vcftools/
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Figure 3.10: Barplots of shared SNPs across all samples(a). Barplot of private
SNPs for sample (b).
3.2.3 Strategy of analysis
The hypothesis of this study is that one or more very rare mutations can be
responsible for T1D within the family. The strategy is to focus on variants
with a strong functional impact, highly penetrant and very rare in Sar-
dinia and elsewhere. Therefore, we expect this variant(s) to be absent in
the other sequenced individuals. We therefore proceeded by assessing the
biological function of each variant and evaluating the frequency in several
data sets, as described below.
The annotation of variants functionality has been performed with Anno-
var tool5, which not only annotate single nucleotide variants and inser-
5http://www.openbioinformatics.org/annovar/
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tions/deletions, but also reports functionally importance scores, as across-
species convservation score. It also annotates the VCF INFO column if the
variant is already reported in the 1000Genomes Project, Exome Sequencing
Project and dbSNP [51]. The variants found in the VCF but absent in these
three datasets were considered Sardinian specific or very rare. In addition
to these annotations, I considered also variants identified in the Sardinian
whole-genome sequencing data reported in the Sardinian sequences refer-
ence panel [24]. We discarded all variants that were common in those four
data sets (frequency> 1%), and retained those that were less frequent or for
which frequency in the population was not reported (as per dbSNP). We
then marked the remaining variants to note those that were present in the
other Sardinian sequenced individuals (low-pass or exome-sequencing)
that are not part of the T1D family under study.
The VCF analysis showed that the total number of variants discovered in
the full exome-sequencing eﬀort (42 individuals) is 150, 812, whom134, 266
are SNPs and 16, 546 are indels. After the Variant Quality Score Recalibra-
tor the total number of variants that passed our quality filters (PASS) is
141, 058 - of those 55, 037 are exonic variants, with diﬀerent exonic func-
tions, as showed in figure 3.11. Focusing only on the aﬀected members
of the family, the number of total PASS variants is 124, 047 and drops to
about 51, 000 when considering only variants with an annotated minor al-
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Figure 3.11: Counts of exonic variants (a). Barplot of exonic variants (b).
lele less than 1% or with unknown frequency. In Figure 3.12 we show the
subsequent criteria used to prioritize variants, when applied to all variants
detected or focusing only on specific biological types.
Despite the number of variants is drastically reduced following these fil-
terings, it was still diﬃcult to discriminate which were shared only by
means of familial inheritance. We therefore considered linkage analysis as
a useful integration to understand which variants fall in regions that are
co-segregating with the disease.
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Figure 3.12: Counts of variants in whole exome sequencing analysis before and
after frequency filtering, comparing all samples and the three aﬀected individuals
of the family.
3.3 Linkage Analysis
To further characterize exome-sequencing findings we carried out linkage
analysis by incorporating genotypes from the Illumina OmniExpress array
and carried out three parametric multipoint linkage analysis. Genotyping
of the OmniExpress array was performed for all 13 members of the family
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togetherwith genotypes for other 2300 Sardinian individuals. Experiments
were carried out in the Lanusei UOS of the IRGB Institute according to
manufacturers protocols, and genotypes called with the Illumina software
GenomeStudio. We performed standard per sample and per SNP quality
checks considering the full set of OmniExpress arrays. Specifically, we
required all samples to have a call rate > 98%, we removed SNPs with
minor allele frequency < 1%, with genotyping call rate < 98%, with strong
deviation fromHardy-Weinberg equilibrium (p < 10−6), or that showed an
excess of Mendelian inconsistencies. We then selected the 13 member of
the T1D family and incorporated, for the 4 that were also sequenced, the
genotype calls derived from exome-sequencing. The merged genotypes
file was created with the option bmerge of Plink tool6 [52] set in modality
merge-mode 2, in order to use as a reference genotypes those from OE
arrays and overwrite if missing in original. Excluding multiallelic SNPs
and indels, the new merged file includes 794, 575 variants, if which 95, 756
are only from sequences and 112, 019were detectedwith bothmethods; the
concordance rate was 90%. Linkage analysis have been performed with
Merlin7 [53]. According with the pattern of inheritance among aﬀected
members, as showed in the pedigree, we hypothesized for the linkage
analysis a dominant model and set the disease allele frequency to 0.01%.
To define population frequencies for linkage modeling, for each variant
6http://pngu.mgh.harvard.edu/purcell/plink/
7http://csg.sph.umich.edu/abecasis/Merlin/
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given as input we estimated the frequency in the 2300 genotyped samples
if was typed with the Omni array, and in the 42 sequenced samples if was
derived with the exome-sequencing.
Figure 3.13: The patients’family tree showing selected individuals in the exome-
seq and linkage analyses.
Moreover, since the program can only handle a limited number of
familymembers, we performed three diﬀerentmultipoint linkage analysis,
evaluating carefully the individuals tobe includedeach time. Themembers
of the first and third generation have always been considered, while there
are diﬀerences in the second generation, resulting in the following three
cases:
• case 1: only cases are included, except the individual II-17 (II-3, II-4,
II-5, II-6, II-7);
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• case 2: all cases (II-3, II-4, II-5, II-6, II-7, II-17);
• case 3: 4 cases and 2 controls (II-3, II-4, II-6, II-17, II-9, II-10). In this
case, II-4 and II-6were chosen because parent of III-15 and individual
with dual pathology respectively, II-10 because sequenced in exome-
sequencing and II-17 given that is the only in the second branch of
the family.
3.3.1 Results
Results of the three parametric linkage analysis are shown in the table 3.1.
All three cases converged on three regions: one on chromosome 2 (2q36.3-
2q37.1), one on chromosome 13 (13q31.2-13q31.3) and one on chromosome
18 (18p11.31). However, only the linkage peak on chromosome 2 contains
one of putatively causing exonic variants (non synonymous SNP in 2q37.1)
detected in exome sequencing analysis.
Furthermore, this suggestive linkage signal had been seen in a previously
genome linkage scan conducted for a part of the family (individuals I-1,
I-2, I-14, II-3, II-4 II-5, II-6, II-7, II-8, II-9, II-10, II-11) using 593 microsatel-
lites markers (398 purchased as commercial kits from Applied Biosystems:
ABI PRISM LINKAGE MAPPING SETS V2.5 and 195 additional markers,
selected in the laboratory). The linkage analysis based on microsatellites
markers, carried out for a dominant model with Merlin, indicates 2q37.1
as the strongest peak along with other suggestive signals on chromosomes
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Chromosome Cytoband LOD Score LOD Score LOD Score
Case 1 Case 2 Case 3
1 p36.12-p36.13 1.8 - -
1 q25.3-q35.1 - - 2.3
2 q36.3-q37.3 1.8 2.4 2.3
3 q26.31-q28 1.8 2.4 -
12 q14.3-q15 1.8 - -
13 q31.2-q31.13 1.8 2.4 1.3
14 q31.3-q32.2 1.8 2.4 -
16 q22.1 - - 2.0
17 q11.2-q21.32 - - 2.3
18 p11.23-p11.31 1.8 2.3 2.3
Table 3.1: Results of parametric multipoint linkage analyses using joint exome-
sequencing and array based genotypes, for case scenarios 1,2 and 3. Positions
refers to the citogenetic location of the peak of LOD scores. LOD scores are
reported if values were > 1.8 in at least one case.
14 (q31.3-q32.2) and 18, as showed in figure 3.14.
Our exome sequencing analyses pointed to variants that fall in one of
the following linkage peaks that are seen in one or two case-scenarios:
on chromosomes 1 (a one-base 3 UTR deletion q32.1), 3 (a 3 UTR SNP in
3q26.33), 12 (a 4-bases 3 UTR deletion in 12q15) and 14 (a 3 UTR SNP in
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Figure 3.14: Results of a parametric multipoint linkage analysis on a part of the
family using microsatellites data.
14q32.12) . Of note, the two SNP variants on chromosome 3 and 14 are
not unique to the family, as they are present in the Sardinian reference
panel with frequency of 0.17% and 0.33% respectively, whereas the 3 UTR
deletions are private variants of this family. We then carried out validation
trough Sanger sequencing of these five variants as well as other seven
resulting only from exome sequencing analyses and that were predicted
to have an high functional impact or that falled in genes with a role in
known autoimmune pathways. The variants were sequenced in all 13
family members. The variants with the most consistent pattern of sharing
between the aﬀected individuals were three:
1. the non synonymous variant on 2q37.1, present in all aﬀected mem-
bers with the sole except of the more distant individual II-17;
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2. the 1-base deletion on chromosome 1 at q32.1, present in all aﬀected
members with the sole exception of II-3;
3. the 4-bases deletion on 12q15 shared among all aﬀected in the family,
except II-11 and II-17.
The variant on 1q32.1 was absent in healthy members, while both
other variants were present also in one healthy individual ( II-8 and II-10
respectively). All other 9 mutations sequenced with Sanger did not show
a pattern of genotypes that was consistent with the hypothesized disease’s
model.
These three variants therefore remain the most candidates and func-
tional assessment of their biological role is now undergoing. The nonsyn-
onymous mutation is not specific to Sardinians but is very rare elsewhere
- it was described in the latest version of 1000 Genomes Project (Phase
3, November 2014) and in the Exome Sequencing Project 6500 with a fre-
quency of 0.020% (1/5008 chromosomes ) and 0.0077% (1/13006 chromo-
somes) respectively. SIFT and Polyphen2 predictions showed a damaging
impact on protein function and a GERP score of 4.96 suggests an high
index of conservation. If we limit to only individuals related to the more
extended branch of the family, this variant shows the best co-segregation
among aﬀected members, although the penetrance is not complete. The
other two deletions have not been previously described in public datasets
and therefore at the moment are private mutations of this family. The
42 Chapter 3. Study design and Methods
genes where those three variants fall are all potential candidates. The non-
synonymous SNP falls within a gene that has been already suggested as
a locus of T2D diabetes susceptibility, impaired glucose tolerance and in-
sulin resistance. The other two deletions are located in the 3 UTR of genes
with established roles in other autoimmune diseases like Celiac Disease
and Multiple Sclerosis.
Chapter 4
Concluding Remarks
In this study I presented an application of exome sequencing data com-
bined with a family-based linkage analysis on a family aﬀected by type 1
diabetes.
The family presented here is unique for its number of aﬀected individuals
with T1D in three generations and co-occurrence of autoimmune diseases
in two family members. The sequencing of 4 individuals, of whom 3 were
aﬀected and selected from diﬀerent generations, produced a large num-
ber of potentially interesting variants that was then reduced to about 2000
variants after the application of several filters. Despite the considerable
reduction of the initial number of variants, the set of candidate variants to
be tested for validation was still too wide. We therefore applied a com-
bined strategy that incorporates exome sequencing with array genotyping
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data for the full family into a linkage analysis to evaluate co-segregation
of these candidate variants with the disease. With this approach, it was
possible to considerably reduce the number of variants to be validated by
Sanger sequencing and consequently narrow the list of candidates to three
mutations that are very rare in the general population (frequency< 0.01%).
The variants fall in genes with a potential involvement in T1D, supporting
that the results are genuine.
None of three mutation show a complete Mendelian co-segregation with
the disease, however heterogeneity is expected in a complex disease such
as T1D and some of the aﬀected individuals can be a sporadic T1D patient.
Moreover, even at the phenotypic level, the family is quite heterogeneous,
not only in the age of onset, but also in the ambiguity concerning the
analysis of autoantibodies, for which some of the healthy individuals were
positive (including the father of the generation I). It is possible that this phe-
notypic diversity can result in heterogeneity at the genetic level. Finally, in
the absence of functional data in support of a biological role in diabetes for
these variants, it cannot be excluded that none of them is causative. Exome
sequencing is indeed not an exhaustive assessment of the genomic varia-
tion therefore other classes of variants not included in this analysis may
be causing the disease. For example, the approach may miss mutations
in exonic regions that were not targeted by the exome-sequencing capture
method utilized. Furthermore, structural exonic or genomic variants, as
copy number variants, were not considered at all. Therefore, further ge-
45
netic characterization, including deep sequencing of key members, could
reveal the presence of other variants causing diabetes in this family.
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